- Leukotriene LTD4 and LTB4 antagonists
-
This invention encompasses compounds of Formula I STR1 and the pharmaceutically acceptable salts and geometrical and optical isomers thereof wherein: X, Y, and Z are each independently O or S with S optionally oxidized to S=O; Alk is straight or branched chain alkylene or hydroxyalkylene containing 1-6 carbon atoms; R1 is hydrogen or lower alkyl; n is 0 to 5; R2 is hydrogen, lower alkyl, cycloalkyl, --(CH2)n --CO2 R1, phenyl, phenyl substituted with halo, lower alkyl or lower alkoxy; and Ar is 5,6,7,8-tetrahydro-1-naphthalenyl, phenyl, or phenyl substituted with lower alkyl, hydroxy, lower alkoxy, or lower alkanoyl. This invention is in the field of pharmaceutical agents which act as leukotriene D4 (LTD4) antagonists and includes embodiments which act as leukotriene B4 (LTD4) antagonists.
- -
-
-
- Leukotriene LTD4 and LTB4 antagonists
-
The invention encompasses compounds of Formula I STR1 and the pharmaceutically acceptable salts and geometrical and optical isomers thereof wherein: X, Y, and Z are each independently O or S with S optionally oxidized to S=O; Alk is alkylene or hydroxyalkylene containing 1-6 carbon atoms; R1 is hydrogen or lower alkyl; n is 0 to 5; R2 is hydrogen, lower alkyl, cycloalkyl, --(CH2)n --CO2 R1, phenyl, phenyl substituted with halo, lower alkyl or lower alkoxy; and Ar is 5,6,7,8-tetrahydro-1-naphthalenyl, phenyl, or phenyl substituted with lower alkyl, hydroxy, lower alkoxy, or lower alkanoyl. The compounds are useful as anti-allergy agents and anti-inflammatory agents.
- -
-
-
- Chemical compounds
-
There are provided compounds of formula I, STR1 wherein R1, R2, R3, R4, R5 and R7 may be the same or different, and are hydrogen, hydroxy, alkoxy, alkoxy substituted by phenyl, acyl, amino, acylamino, alkenyl, halogen, or alkyl, provided that at least one of R1, R2, R3 and R7 are other than hydrogen and hydroxy, Or an adjacent pair of R1, R2, R3 and R7 represent a chain --COCH=CH--O--, X is a hydrocarbon chain containing from 2 to 10 carbon atoms and optionally substituted by a hydroxy group, and E is a carboxy group or a tetrazole group, And pharmaceutically acceptable derivatives thereof. The compounds are indicated for use as antagonists of SRS-A.
- -
-
-